Comparative Pharmacology
Head-to-head clinical analysis: EDOXABAN versus HEPARIN SODIUM 10 000 UNITS IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDOXABAN versus HEPARIN SODIUM 10 000 UNITS IN DEXTROSE 5.
EDOXABAN vs HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective, direct, reversible inhibitor of factor Xa, blocking the conversion of prothrombin to thrombin, thereby reducing thrombin generation and thrombus formation.
Heparin binds to antithrombin III, inducing a conformational change that accelerates the inhibition of thrombin (factor IIa) and activated factor X (Xa), thereby preventing clot formation and extension.
60 mg orally once daily
IV continuous infusion: initial bolus 80 units/kg, then maintenance 18 units/kg/hour; titrate to aPTT 1.5-2.5 times control. The solution HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% is typically used for continuous infusion; dose should be adjusted based on patient weight and aPTT.
None Documented
None Documented
Terminal elimination half-life is 10-14 hours. In patients with creatinine clearance 15-50 mL/min, half-life is prolonged to approximately 17-20 hours.
Terminal elimination half-life is 1.5-2 hours (mean 1.6 h) at therapeutic doses, but is dose-dependent: 30-60 min after 25 U/kg, 1-2 h after 100-200 U/kg, and 2.5-5 h after 400-800 U/kg. Half-life is prolonged in hepatic or renal impairment.
Renal excretion accounts for approximately 50% of the administered dose. Fecal excretion accounts for approximately 40%. Biliary excretion is minimal.
Heparin is eliminated primarily via the reticuloendothelial system and renal excretion. Approximately 50% is excreted unchanged in urine via saturable zero-order kinetics, with the remainder metabolized to uroheparin and other inactive metabolites. Biliary/fecal excretion is negligible (<5%).
Category C
Category A/B
Anticoagulant
Anticoagulant